tiprankstipranks
Exscientia announces 1st- in-human trial for Bristol-Myers in-licensed EXS4318
The Fly

Exscientia announces 1st- in-human trial for Bristol-Myers in-licensed EXS4318

Exscientia (EXAI) announced that EXS4318 a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb (BMY) in August 2021, has entered Phase 1 clinical trials in the United States. The compound is in development for immunology & inflammation indications. Bristol Myers Squibb will oversee the clinical and commercial development and Exscientia is eligible for milestone payments and, if approved, tiered royalties on net product sales. "We are excited for Bristol Myers Squibb to begin clinical evaluation of ‘4318, the first Exscientia I&I candidate to enter the clinic. PKC theta is an attractive immune modulating drug target; however, it has been challenging for the field to design a small molecule with the required potency as well as selectivity against other closely related kinases," said David Hallett, Ph.D., Chief Scientific Officer at Exscientia. "Our expert-led AI design platform was able to deliver a balanced candidate which has demonstrated high on-target activity while maintaining high selectivity and favourable therapeutic index in IND-enabling studies. This is a significant milestone for Exscientia that illustrates the strength and flexibility of our precision design platform in efficiently developing high quality therapeutics."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on EXAI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles